NCT06487624 2026-02-05
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
FBD Biologics Limited
Phase 1 Recruiting
FBD Biologics Limited
Eli Lilly and Company
Pfizer
EMD Serono
Suzhou Transcenta Therapeutics Co., Ltd.